• 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 2
    Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132( 3 suppl): 29S-55S.
  • 3
    Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008; 32: 1822-1834.
  • 4
    Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995; 26: 873-879.
  • 5
    Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. New York, NY: Springer; 2002: 91-98.
  • 6
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111: 1710-1717.
  • 7
    Detterbeck FC. Lumping, splitting, and sorting. J Thorac Oncol. 2007; 2: 581-582.
  • 8
    Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991; 68: 2142-2149.
  • 9
    Murphy GP, Busch C, Abrahamsson PA, et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl. 1994; 162: 7-42; discussion 115-127.
  • 10
    Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6: 655-663.
  • 11
    Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
  • 12
    Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32: 810-827.
  • 13
    Chung CK, Zaino R, Stryker JA, O'Neill M Jr, DeMuth WE Jr. Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg. 1982; 33: 599-604.
  • 14
    Takise A, Kodama T, Shimosato Y, Watanabe S, Suemasu K. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer. 1988; 61: 2083-2088.
  • 15
    Petersen I, Kotb WF, Friedrich KH, Schluns K, Bocking A, Dietel M. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer. 2009; 65: 312-318.
  • 16
    Kobayashi N, Toyooka S, Soh J, et al. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. J Thorac Oncol. 2007; 2: 808-812.
  • 17
    Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol. 2008; 32: 1896-1904.
  • 18
    Cho S, Sung SW, Jheon S, Chung JH. Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis. Lung. 2008; 186: 411-419.
  • 19
    Lester SC. Manual of Surgical Pathology. 2nd ed. New York, NY: Elsevier Churchill Livingstone; 2006.
  • 20
    Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg. 2006; 81: 1988-1995.
  • 21
    Jemal A, Thun MJ, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
  • 22
    Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst. 2008; 100: 1755-1762.
  • 23
    Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol. 2002; 13: 1087-1093.
  • 24
    Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y. Surgically curable “early” adenocarcinoma in the periphery of the lung. Am J Surg Pathol. 1994; 18: 431-438.
  • 25
    Amin MB, Tamboli P, Merchant SH, et al. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol. 2002; 26: 358-364.
  • 26
    Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol. 2003; 27: 101-109.
  • 27
    Ohtsuka K, Ohnishi H, Furuyashiki G, et al. Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol. 2006; 1: 787-795.
  • 28
    Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res. 2004; 10: 7311-7317.